Individuals aboard jet aircraft may be exposed to potentially toxic triaryl organophosphate antiwear lubricant additives (TAPs) that are converted by cytochromes P450 into toxic metabolites. Consequences of exposure could be reduced by using less toxic TAPs. Our goal was to determine whether an in vitro assay for inhibition of butyrylcholinesterase (BChE) by bioactivated TAPs would be predictive of inhibition of serine active-site enzymes in vivo. The in vitro assay involved TAP bioactivation with liver microsomes and NADPH, followed by incubation with human BChE and measurement of BChE activity. Of 19 TAPs tested, tert-butylated isomers produced the least BChE inhibition. To determine the relevance of these results in vivo, mice were exposed to Durad Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
Introduction
On most jet turbine aircraft, unfiltered engine bleed air is fed into the cabin, providing oxygen for those aboard [1] . Exposure of passengers and crew to some level of triaryl phosphates (TAPs) occurs in approximately 23% of monitored flights [2, 3] , whereas higher levels of exposure can occur when engine seals wear or fail. Symptoms of aerotoxic syndrome resulting from such exposures can include extreme mental impairment [4] , an acute flight safety issue when crew exposure to contaminated air is significant. Material safety data sheets for synthetic jet lubricants list TAP contents of 1-10%.
Neurotoxicity of aromatic phosphate esters to humans was first reported in 1899, following treatment of tuberculosis patients with phosphocreosote [5] . Studies in 1930 examining the cause of Ginger Jake paralysis, which affected 10,000 to 50,000 individuals consuming extracts of ginger adulterated with tri-cresyl phosphate (TCP), identified tri-(o-cresyl) phosphate (ToCP) as the paralytic agent [6, 7] . Epidemic poisonings have since been associated with consumption of food adulterated with TCPs [8] [9] [10] [11] [12] [13] .
In the early 1950s, Aldridge reported that liver metabolism of ToCP was required to generate toxic metabolite (s) [14] . In 1961, Casida et al. [15] reported the toxic metabolite of ToCP to be 2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one (CBDP, or cyclic saligenin cresyl phosphate), which has since been shown to be an inhibitor of several serine active-site esterases including butyrylcholinesterase (BChE) [16] , acetylcholinesterase (AChE) [17] , carboxylesterase (CES) [18] [19] [20] and acylpeptide hydrolase (APH) [21] . The in vitro role of microsomes in the metabolism of TAPs, including ToCP, was established by Sprague and Castles in 1985 [22] . An analogue of CBDP, phenyl saligenin phosphate [23] , is a potent inhibitor of neuropathy target esterase (NTE) [24] , the inhibition and aging of which results in organophosphate (OP)-induced delayed neuropathy (OPIDN) [25] . Toxic metabolites of other jet engine TAP additives, including those evaluated in this study, have not yet been described in the literature.
The purpose of the present study was to develop an in vitro assay for assessing the inhibitory potential of TAPs using the biomarker esterase, BChE [26] , and to verify the in vitro results with in vivo exposures of mice. Mice were exposed by gavage to a commercial TCP mixedisomer formulation, Durad 125 (D125), and to two TAPs found not to inhibit BChE with the in vitro bioactivation assay, tri-(o-tert-butylphenyl) phosphate (TpBP) and tri-p-cresyl phosphate (TpCP). The three compounds were compared for their ability to inhibit serine active-site enzymes from plasma, RBCs, liver and brain. Finally, because the flavonoid compound, naringenin, has been shown to inhibit cytochromes P450 [27] we examined its effect on bioactivation of D125.
Materials and methods

Chemicals and supplies
N-Acetyl-L-alanyl-p-nitroanilide (AcAlaPNA) was from Bachem (Torrance, CA); Paraoxon from Chem Service (West Chester, PA); NADPH from RPI (Mt. Prospect, IL); anti-poly-His antibody from Invitrogen (Grand Island, NY); acetylthiocholine, S-butyrylthiocholine iodide, 5,5'-dithio-bis-nitrobenzoic, p-nitrophenyl valerate (PNV), phenyl valerate (PV), alpha-naphthyl butyrate (αNB), methyl umbelliferyl acetate (MUA), potassium ferricyanide, and 4-aminoantipyrine from Sigma (St. Louis, MO); microplates (96-well, flat bottom) for visible light or UV range (Greiner Bio-One) were purchased from Fisher Scientific (Hanover Park, IL). Mice were from Taconic Farms (Germantown, NY). Mipafox and CBDP were gifts from Drs. Marion Ehrich and Oksana Lockridge, respectively. Table 1 shows the source and purity for TAPs that were used.
Rat liver microsomes (RLMs)
RLMs were leftover samples from male Sprague-Dawley rats (150 -200 g) injected intraperitoneally for four days with 80 mg/kg/day phenobarbital [28] and stored at -80° C in 50 mM sodium phosphate, pH 7.4 (buffer A).
Microsomal bioactivation of TAPs
Solutions of TAPs were prepared at 2.5 mg/ml in ETOH, then diluted 1:62.5 (to 40 μg/ml) prior to making serial dilutions and addition to RLMs and NADPH in buffer A. Final concentrations in the bioactivation step were 14 mg/ml RLMs, 1 mM NADPH and TAPs at concentrations, up to 20 μg/ml. Bioactivation proceeded for 25 min at 25°C, when 10 μl of purified human BChE [29] (1.33 μg/ml in DD H 2 O) were added, followed by incubation for an additional 25 min.
Measurement of BChE activity
BChE activity was determined by a kinetic modification of the Ellman procedure [30] , adapted for continuous monitoring with a SpectraMax Plus 384 plate reader (Molecular Devices). Kinetic data were acquired at 405 nm for 4 min using SoftMax Pro software, with path length correction. Only linear initial reaction rates (< 4 min) were used for analyses.
Expression and properties of the rNEST domain of NTE
Cloned rNEST was expressed (with a C-terminal His 6 tag), purified, and incorporated into dioleoylphosphatidyl-choline liposomes as previously described [31] , except without an Nterminal tag. Since RLMs contained high levels of PV-hydrolyzing enzyme (s), interfering with measurement of rNEST activity, CBDP (the metabolite of bioactivated ToCP) was used to determine the direct effect TCP metabolites on BChE and rNEST.
Suppression of D125-mediated inhibition of BChE by naringenin
RLMs and NADPH were pre-incubated (20-25 min) with naringenin (0, 0.2, 2.0, 20 and 200 nM) in buffer A, then D125 (0.36 μg/ml; equivalent to its IC 50 for BChE inhibition) was added to the mixture for an additional 20-25 min. One set of controls contained no naringenin and another contained no D125. BChE activity was determined as described above.
Administration of TAPs to mice
All animal experiments were in compliance with the Guiding Principles in the Use of Animals in Toxicology [32] , and approved by the University of Washington IACUC. Mice (7-9 weeks old male C57Bl/6) were housed in a SPF facility with food and water ad libitum.
TAPs were dissolved at 25 mg/ml directly in warm corn oil (55°C), diluted in corn oil to the desired concentration, cooled (25°C) and administered to mice by gavage (10 μl/g body weight). Control mice received vehicle (corn oil) alone.
Preparation of tissue samples
At 6 hr post-exposure, mice were assessed for signs of morbidity and blood was collected from the saphenous vein in heparinized capillary tubes. Plasma and RBCs were separated by centrifugation (1000 rcf for 10 min). RBCs were washed 3X with PBS, and both plasma and RBCs were stored at -80°C. At 24 hr post-exposure, mice were euthanized by CO 2 asphyxiation. Following decapitation, trunk blood was collected in heparinized tubes and processed as above. Brains and livers were also harvested and homogenized (4°C) in PotterElvehjem homogenizers. Brains were homogenized in 5 volumes (w/v) of sodium phosphate (50 mM, pH 8.0, 4°C), while livers were homogenized in 10 volumes (w/v) of Tris (100 mM, pH 8.0, 4°C). Both homogenates were centrifuged (700 rcf for 10 min) and supernatants stored at -80°C.
Enzyme assays in mouse blood and tissues
BChE activity of mouse plasma samples was measured as described in section 2.4 above, except 100 μl of plasma samples (1:50 dilution in buffer A) were used. APH activity in RBCs was measured by hydrolysis of αNB [33] . Ten μl of thawed blood cell lysate (1:20 dilution in 20 mM Tris, pH 7.0) were added to 200 μl αNB reaction mix (200 μM α-napthyl butyrate in the same buffer). Substrate hydrolysis was measured continuously at 235 nm (4 min at 25°C). Liver APH activity was determined with a modified assay of Quistad et al. [21] . Liver homogenate supernatant (above) was diluted to 100 μg/ml (100 mM Tris, pH 7.5) and 185 μl was added to microplate wells along with 1.5 mg/ml AcAlaPNA (100 μl in the same buffer). Formation of p-nitroanilide was measured continuously at 405 nm (10 min at 37°C). Plasma CES or CES1C [34] activity was measured with two different substrates, PNV and MUA. Rates of PNV hydrolysis were quantified by a modification of the protocol of Munger et al. [35] . Twenty μl of plasma (1:50 in 50 mM Tris, pH 8.0) were added to microplate wells, followed by 200 μl of freshly-prepared PNV substrate mix (1 mM PNV in 50 mM Tris, pH 8.0). Formation of p-nitrophenol was monitored continuously (10 min at 25°C) at 405 nm. The MUA hydrolysis assay for plasma and liver CES was adapted from Brzezinski et al. [36] , with kinetic modifications. Twenty μl of liver supernatant, adjusted to 1 mg/ml (50 mM Tris, pH 8.0) or diluted plasma (1:50, same buffer) were added to microplate wells, followed by 200 μl of MUA (5 μg/ml in the same buffer containing 1 mM EDTA). Rates of hydrolysis were monitored continuously at 354 nm for 4 min. The brain NTE assay was adapted from Winrow et al. [37] with kinetic modifications. Brain supernatants were incubated with mipafox (50 μM) and/or paraoxon (PO, 40 μM) for 20 min at 37°C, then 60 μl were added to microplate wells with 150 μl PV assay mix, also at 37°C. Formation of 4-N-(1,4-benzoquinoneimine)-antipyrine was monitored continuously at 510 nm (15 min 37°C). NTE activity was considered to be that portion of PV-hydrolyzing activity that was insensitive to PO inhibition but sensitive to mipafox inhibition.
Initial linear rates of product formation (mOD/min) for each enzyme were converted to Units per ml (U/ml) using pathlength correction and the respective extinction coefficients: α-napthol, 24.2 mM -1 cm -1 ; p-nitroaniline, 8.8 mM -1 cm -1 ; p-nitrophenol, 18 mM -1 cm -1 ; 4-methylumbelliferone, 12.2 mM -1 cm -1 ; 4-N-(1,4-benzoquinoneimine)-antipyrine, 13.9 mM -1 cm -1 .
Statistical analyses
In vitro data were graphed using Microsoft Excel. Results are presented as percent of control and are shown as the mean ± SEM or mean ± SD, as indicated. Differences in enzyme inhibition among TAP compounds in vivo were tested for statistical significance with Student's t-test followed by a Bonferroni correction for multiple testing. Values for halfmaximal inhibitory concentrations (IC 50 ) in vitro and half-maximal effective doses (ED 50 ) in vivo were calculated with Prism software (GraphPad v. 5.03, San Diego, CA) using nonlinear regression (curve fit) vs. normalized responses.
Results
Development and testing of the in vitro BChE inhibition assay
Initial experiments, performed to optimize concentrations of RLMs and NADPH for bioactivation of TAPs (25°C for 25-30 min), were evaluated by determining IC 50 values (data not shown). D125 bioactivation, measured by BChE inhibition under optimized conditions, had a mean IC 50 value (± SD) of 0.36 ± 0.06 μg/ml (9 experiments, each in triplicate) (Fig. 1A) . Identical conditions were used for testing 18 additional TAPs (Table 1) , where D125 was included as a positive control for inhibition with each set of TAPs assayed. An example of using D125 as a standard across individual experiments is shown in Figure  1B , where ToCP and TpBP were bioactivated along with D125. Bioactivated ToCP (IC 50 = 0.12 μg/ml) was approximately three times more inhibitory to BChE than bioactivated D125 (IC 50 = 0.36 μg/ml), whereas bioactivated TpBP did not inhibit BChE at levels up to 20 μg/ ml. BChE was not inhibited by any TAP in the absence of NADPH (Fig. 1C) . Bioactivation of TpCP or any tert-butylphenyl phosphate (TBP) isomer (tri-o, tri-m-or tri-p-) generated no BChE inhibitor (s) (Fig. 1D) . The IC 50 values and additional information for the 19 different TAPs examined are summarized in Table 1 .
Inhibition of the rNEST domain of NTE
Three OP compounds were tested for inhibition of rNEST. Exposure of rNEST to 40 μM paraoxon (PO) and 50 μM mipafox demonstrated that purified rNEST exhibited the classic catalytic properties of NTE, inhibition insensitive to PO but sensitive to mipafox inhibition (not shown). CBDP inhibited rNEST with an IC 50 value of 40 ng/ml (109 nM) ( Fig. 2A) . BChE was more sensitive to CBDP inhibition with an IC 50 value = 7 ng/ml (19 nM) (Fig.  2B ).
Naringenin inhibition of D125 bioactivation
The protocol developed to examine TAP inhibition of BChE in vitro was modified to examine the effect of pre-incubation with varying concentrations of naringenin. Preincubation of RLMs/NADPH with naringenin resulted in a concentration-dependent reduction of D125 bioactivation from (Fig. 3) . In the absence of D125, naringenin had no effect on BChE activity.
Effects on serine active-site hydrolases
Pilot studies in mice established the dose range and most efficacious route of TAP exposure for in vivo studies. None of the routes of TAP exposure (IP, dermal, or gavage) or dosage level examined (as great as 240 mg/kg body weight) resulted in overt toxicity following single exposures. Exposure by gavage produced the greatest and most consistent inhibition of enzyme activity (data not shown) and was used for further experiments.
Three TAPs (D125, TpBP and TpCP) were administered to mice by gavage at doses of 10, 60, 120, and 240 mg/kg in corn oil. Vehicle (corn oil) alone was administered to the control group. Effects of TAP exposure on blood, brain and liver enzymes were examined 6 hr postexposure (for plasma and RBCs enzyme levels) and 24 hr post-exposure (for plasma, RBCs, liver and brain levels). For RBC and plasma enzymes, inhibition differences between the 6 and 24 hr time points were statistically insignificant, so only the latter data are reported.
D125 exposure inhibited > 60% of plasma BChE at all but the lowest dose tested, whereas TpCP inhibited only 20% plasma BChE at the highest exposure dose (240 mg/kg), and TpBP did not inhibit BChE at any dosage level (Fig. 4A ). D125 and TpCP exposure resulted in modest but significant inhibition of RBC APH activity (measured by αNB hydrolysis) at 240 mg/kg, whereas TpBP did not inhibit RBC APH at any dosage level (Fig. 4B) . All three TAPs significantly reduced plasma CES activity measured by PNV (Fig. 4C) or MUA (Fig.  4D) hydrolysis; however, plasma CES inhibition by TpBP was again less than that observed with D125 or TpCP. D125 and TpCP significantly reduced liver APH activity (measured by AcAlaPNA hydrolysis, a more specific APH substrate than αNB) (Fig. 4E) , and CES activity (measured by MUA hydrolysis) (Fig. 4F) at all exposure levels. TpBP exposure did not significantly inhibit liver APH (measured by AcAlaPNA hydrolysis) (Fig. 4E) or CES activity (measured by MUA hydrolysis) (Fig. 4F) at any exposure level.
ED 50 values from the in vivo exposures are shown in Table 2 . In plasma, the ED 50 value for D125 was 63 mg/kg for BChE, whereas for TpCP and TpBP the ED 50 values were >240 mg/kg (Fig. 4A , Table 2 ). The ED 50 values for all three TAPs were also >240 mg/kg for RBC APH (measured by αNB hydrolysis) (Fig. 4B) . In RBCs, the ED 50 values for all TAPs were > 240 mg/kg for APH ( Table 2 ). The ED 50 value for D125 inhibition of plasma CES was 19 mg/kg (measured by MUA or PNV hydrolysis) (Figs. 4C, D; Table 2 ). In plasma, ED 50 values for CES inhibition by TpCP (measured by PNV or MUA) were 27 and 17 mg/ kg, respectively. The ED 50 values for TpBP inhibition of plasma CES, measured by PNV (93 mg/kg) or MUA (86 mg/kg), were significantly greater than those of TpCP or D125 ( Fig  4D, Table 2 ). In liver, the ED 50 values for TpBP were >240 mg/kg for both APH and CES (Figs. 4E, F, Table 2 ). D125 and TpCP both significantly inhibited liver CES (ED 50 = 85 and 52 mg/kg, respectively) and APH (ED 50 = 33 and 14 mg/kg, respectively).
Brain homogenates from control and TAP-treated mice were compared for NTE activity by measuring the PV-hydrolyzing activity that was insensitive to 40 μM PO but sensitive to 50 μM mipafox. NTE was not significantly inhibited by these single exposures at any dosage level (not shown). Similarly, brain AChE activity was not inhibited by any of the TAPs following the single in vivo exposure (not shown).
Discussion
Exposures of individuals aboard jet aircraft to aerosolized TAPs represent a serious health concern [1, 29, 38, 39] . Because pressurization is necessary for proper engine seal function, exposure to aircraft engine lubricants containing TAPs occurs during "fume events", engine start-up/shut-down on the ground, and throughout "uneventful" flights during normal acceleration or deceleration [1] [2] [3] . Exposures to aerosolized jet engine lubricants are poorly documented and are often overlooked by airline industries [38] . Boeing's new 787 "Dreamliner" does not use bleed air to condition the cabin [40] . For the foreseeable future, however, there will be of thousands of aircraft still using bleed air to provide air for passengers and crew, with accompanying possibilities of TAP exposure. Therefore, it makes sense to develop lubricant formulations that are less toxic than current formulations.
We describe here a rapid in vitro assay for identifying potentially safer TAP lubricant additives, and have validated the potential safety of some of these TAPs by in vivo exposure of mice. To date, almost all studies on the safety of TAP-containing compounds involved chronic exposure of chickens followed by evaluation of neuropathology and/or symptoms of OPIDN [22, [41] [42] [43] [44] , although rodents have also been used to examine the effect (s) of TAP exposure [42, 45] TAP bioactivation provided a rapid evaluation of 19 different parent compounds in vitro, using inhibition of BChE. None of the TAPs or commercial OP additive formulations inhibited BChE without both RLMs and NADPH (Figs. 1B, C) , implicating the cytochrome P450 superfamily in the bioactivation of the TAPs. Nine TAP formulations tested were not bioactivated at their limits of solubility (~20 μg/ml) ( Table 1) . Bioactivated ToCP produced the most potent BChE inhibition (IC 50 values = 0.12 μg/ml -0.15 μg/ml, or 330 nM). The D125 IC 50 value was 0.36 μg/ml (± 0.06). Human liver microsomes (University of Washington, School of Pharmacy Human Tissue Bank) also bioactivated TAPs in the presence of NADPH (not shown), but limited availability precluded their use for extensive analyses.
For in vivo validation, TpCP, TpBP, and D125 were administered to mice by gavage.
Gavage exposure was determined in pilot studies to be a more appropriate route than dermal or IP exposure, and administration by aerosol was not feasible because of regulatory restrictions on inhalation exposures in our shared animal housing. D125 was chosen as a positive control for the in vivo studies, since it is used commercially and was also used as the in vitro control. TpCP and TpBP were selected because they generated no BChE inhibition in vitro (Table 1) . Further, others reported tri-p-substituted phenyl phosphates like TpCP to be less toxic than m-and o-substituted TAPs, and chronic exposure studies using the hen model of OPIDN reported relatively low toxicity of butylated TAP-containing formulations [46] . TpBP was especially interesting because none of the tert-butylated TAPs inhibited BChE in vitro, and TpBP exposures produced no BChE inhibition in vivo.
Efficacy of target enzyme inhibition is likely related to TAP bulkiness or substituted aryl group (s) geometry, which may interfere with access to active-site serines [47] . TAPs with bulkier substitutions (e.g., TpBP and the tri-isopropyl-phenyl phosphates) were generally less inhibitory for esterases while bioactivated methyl-substituted TAPs were more efficient esterase inhibitors (Table 1) . However, the product (s) of bioactivated TpCP did not readily reach/bind to the BChE serine active-site, but effectively inhibited the active-site serine of other enzymes (e.g., plasma and liver CESs and liver APH) ( Table 2 ).
Different enzymes exhibit dramatically different sensitivities to inhibitory TAP metabolites. Consistent with the CES inhibition by TAPs in this study (Figs. 4C,D,F, Table 2 ), Quistad and Casida reported the high sensitivity of CES to CBDP inhibition [24] . APH, reported to be involved in cognition [48, 49] , was inhibited in vivo by TAP metabolite (s) (Fig. 4E , Table 2 ). Inhibition and subsequent aging of NTE, a protein important for neuronal transport, may lead to paralysis if significantly inhibited following repeated exposure of animals to neurotoxic OPs [25, 46, [50] [51] [52] . The rNEST catalytic domain of NTE [31, 53] was sensitive to CBDP (IC 50 = 109 nM) ( Fig. 2A) , although BChE was even more sensitive to CBDP (IC 50 = 19 nM) (Fig. 2B) , in close agreement with the 30 nM IC 50 of the related compound, phenyl saligenin cyclic phosphonate [24] . While CBDP was ~6 times more effective at inhibiting BChE than rNEST, it was nonetheless a potent inhibitor of both enzymes.
Since it is clear from this study and interpretation of earlier studies of Aldridge with rat liver slices [14] that the P450 system is required for conversion of TAPs into toxic metabolites, we investigated whether naturally occurring inhibitors would block the conversion of TAPs to toxic metabolites. As show in Figure 3 , naringenin, a compound found in grapefruit, inhibited conversion of D125 into BChE inhibitor (s) in a concentration-dependent manner. The inhibition was observed at concentrations that fall well below the reported ~6 μM concentration of naringenin observed in plasma following ingestion of grapefruit juice [54] . Lu et al. [27] recently described the naringenin enantiomer-dependent inhibition of cytochromes CYP19, CYP2C9, CYP2C19, and CYP3A by the (R)-and (S)-enantiomers of naringenin. Additional research will be required to determine which of the P450 isomers are involved in the bioactivation of each of the TAPs and which naringenin enantiomer is the most potent inhibitor of the bioactivation of a specific TAP by a relevant P450 isozyme. While consumption of grapefruit juice following an exposure may possibly block the conversion of TAP to toxic inhibitor, an important caveat comes from the observation that the microsomal/NADPH system is also involved in the inactivation of active metabolite (s) (data not shown). Aldridge [14] had observed in his earlier studies that incubation of ToCP with liver slices for extended periods of time decreased toxicity following bioactivation.
As normal neuronal function depends on many serine active-site enzymes, in vitro analysis of a representative panel of these enzymes would be informative. The in vivo data reported here suggest that such a panel should include, at least, APH, CES (s) and BChE. Because rNEST is not stable over time and must be incorporated into lipid bilayers for functionality [31] , it would not yet be included in such a panel. The metabolites of TAPs that maximally inhibit the panel of enzymes would merit further toxicological testing. Availability of human cDNAs encoding additional enzymes should facilitate generation of future screening panels.
Conclusions
In summary, in vitro testing of 19 TAPs for bioactivation into esterase inhibitors narrowed the focus of this study to three compounds for further in vivo testing. TpBP was significantly less inhibitory than TpCP or D125, suggesting that TpBP, or a similar compound based on its molecular characteristics, should be a safer anti-wear additive for jet engine lubricants, provided its performance characteristics meet those of similar TAPcontaining formulations currently in use (e.g., D125). An inhibitory effect of the flavonoid naringenin on the bioactivation of D125 into BChE inhibitor (s) was also demonstrated, however, additional studies are required to determine if it might help modulate the effects of TAP exposures. Concentration dependence of D125 bioactivation by naringenin inhibition in vitro. Triplicate samples of RLMs containing NADPH were treated in the following order: 1) naringenin incubation (concentration on x axis); 2) incubation with D125 at its IC 50 level for BChE inhibition, 0.36 μg/ml; 3) incubation with purified human BChE; 4) assay for BChE activity. One triplicate set of assays contained no D125 to serve as a control value. An additional triplicate set of assays contained D125 but no naringenin (not shown). Data points represent percent of the no-D125 control (mean ± SD). Inhibition of enzyme activities from mice exposed to TAPs. Activity measurements were made 24 hr post-gavage exposure of mice. Data points represent percent of control (mean ± SEM) from tissues of 6 mice at each TAP dosage level, assayed in triplicate. Dose response of TAP exposures: (A) plasma BChE activity; (B) RBC APH activity measured by αNB hydrolysis; (C) plasma CES activity measured by PNV hydrolysis; (D) plasma CES activity measured by MUA hydrolysis; (E) liver APH activity measured by AcAlaPNA hydrolysis, and; (F) liver CES activity measured by MUA hydrolysis. Values that were significantly different from controls by Student's t-test are indicated with * (p < 0.02), ** (p < 0.01) or *** (p < 0.001). 
